granisetron hydrochloride

(redirected from Granisol)

granisetron hydrochloride

Granisol, Kytril, Sancuso

Pharmacologic class: 5-hydroxytryptamine3 antagonist

Therapeutic class: Antiemetic

Pregnancy risk category B


Binds to serotonin receptors in chemoreceptor trigger zone and vagal nerve terminals, blocking serotonin release and controlling nausea and vomiting


Injection: 1 mg/ml

Oral solution: 2 mg/10 ml in 30-ml bottles

Tablets: 1 mg

Transdermal system (patch): 52-cm2 patch (containing 34.3 mg granisetron delivering 3.1 mg/24 hours)

Indications and dosages

To prevent nausea and vomiting caused by chemotherapy

Adults and children ages 2 to 16: For I.V. use, 10 mcg/kg I.V. within 30 minutes before chemotherapy. For P.O. use (adults only), 1 mg P.O. b.i.d., with first dose given at least 1 hour before chemotherapy and second dose given 12 hours later on days when chemotherapy is administered; or 2 mg P.O. daily at least 1 hour before chemotherapy. For transdermal use (adults only), apply patch for up to 7 days.

To prevent nausea and vomiting caused by radiation therapy

Adults: 2 mg P.O. daily within 1 hour of radiation therapy

Acute postoperative nausea and vomiting

Adults: 1 mg I.V. undiluted, administered over 30 seconds


• Hypersensitivity to drug


Use cautiously in:
• pregnant or breastfeeding patients
• children younger than age 18 (safety of P.O. and transdermal use not established)
• children younger than age 2 (safety of I.V. use not established).


• For I.V. infusion, dilute with 20 to 50 ml of normal saline solution or dextrose 5% in water.
• Infuse I.V. over 5 minutes, starting 30 minutes before chemotherapy.
• For direct I.V. injection, give undiluted over 30 seconds.
• Don't mix I.V. form with other drugs.
• For P.O. use, give first dose 1 hour before chemotherapy and second dose 12 hours after first.
• Apply a single transdermal patch to upper outer arm for 24 to 48 hours before chemotherapy.
• Remove patch a minimum of 24 hours after chemotherapy completion. Patch may be worn up to 7 days depending on duration of chemotherapy.

Adverse reactions

CNS: headache, anxiety, stimulation, weakness, drowsiness, dizziness

CV: hypertension

GI: nausea, vomiting, diarrhea, constipation, abdominal pain

Hematologic: anemia, leukopenia, thrombocytopenia

Skin: alopecia, application site reactions (patch)

Other: altered taste, decreased appetite, fever, chills, shivering


Drug-diagnostic tests.Alanine aminotransferase, aspartate aminotransferase: increased levels

Electrolytes: altered levels

Hemoglobin, platelets, white blood cells: decreased levels

Drug-herbs.Horehound: enhanced serotonergic effects

Patient monitoring

• Monitor hepatic enzyme levels and CBC with white cell differential.
• Monitor temperature and blood pressure. Have patient use caution when ambulating, to avoid orthostatic hypotension.
• Know that patch may be degraded by direct exposure to natural or artificial sunlight.

Patient teaching

• Instruct patient to apply a single transdermal patch to upper outer arm 24 to 48 hours before chemotherapy.
• Instruct patient to remove patch by gently peeling it off in a minimum of 24 hours after chemotherapy completion.
• Instruct patient to remove patch if a severe or generalized skin reaction (such as rash or itching) occurs.
• Advise patient to avoid direct exposure of application site to natural or artificial sunlight by covering site with clothing while wearing patch and for 10 days after patch removal.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• Advise patient to minimize GI upset by eating frequent, small servings of healthy food.
• Tell patient he'll undergo regular blood testing during therapy.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests and herbs mentioned above.

Mentioned in ?
References in periodicals archive ?
rights to PediatRx's GRANISOL (granisetron HCI) oral solution, the only FDA-approved, oral, ready-to-use liquid solution of granisetron and (2) the assignment of U.
For additional safety information about GRANISOL, please see the "About GRANISOL" section below.
Under the term sheet for the Co-Promotion and Sale Agreement, Apricus Bio will receive rights to co-promote GRANISOL and AQUORAL in the U.
Our agreement with Apricus Bio offers PediatRx the opportunity to simultaneously accelerate the commercial value of GRANISOL in the U.
Continued implementation of sales and marketing initiatives to support GRANISOL and AQUORAL sales.
Agreements with key wholesalers, distributors and group purchasing organizations to support the commercialization and future growth of GRANISOL and AQUORAL sales.
Approval by the Center for Medicare and Medicaid Services to include PediatRx's GRANISOL on the list of reimbursed products for Medicaid and the Section 340B Drug Pricing Program.
Continue to market the merits of GRANISOL and AQUORAL to healthcare professionals, payers, end users and their caregivers.
The only FDA-approved oral solution of granisetron, GRANISOL, is now available to patients enrolled in Medicaid
Centers for Medicare and Medicaid Services (CMS) recently notified state Medicaid agencies to include PediatRx's GRANISOL, NDC 52547-0801-30, in their list of reimbursed products.
Cameron Durrant, founder of PediatRx, said, "We are delighted to have reached an agreement with CMS to include PediatRx's GRANISOL on the list of reimbursed products for Medicaid.
States can begin covering GRANISOL at their option any time between these two dates.